Search
Eptinezumab
go.drugbank.com/drugs/DB14040ApprovedInvestigationalEptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals. … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]
Damoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigational[L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609] … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized.
Ceforanide
go.drugbank.com/drugs/DB00923ApprovedIts activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. … Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species
Synonyms: 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acidPatisiran
go.drugbank.com/drugs/DB14582ApprovedPatisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220]. … It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced.
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigational[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.
Sulfanilamide
go.drugbank.com/drugs/DB00259ApprovedWithdrawnSulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.
Capsicum oleoresin
go.drugbank.com/drugs/DB11131ApprovedDue to its analgesic properties, capsicum oleoresin is used to temporarily relieve of minor aches and pains of muscles and joints as an active ingredient in topical OTC preparations and has been studied
Mixtures: Herbalax Forte No 70 Tab, HO YAN HOR MEDICATED OILCentanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … relief was observed to be 8 hours compared to 36 hours for the placebo treatment.
Categories: Analgesics, Non-NarcoticFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … [L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770]